Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: Phase 3 adapt study results

Authors
Category Primary study
JournalJournal of the Neurological Sciences
Year 2021
This article has no abstract
Epistemonikos ID: 5dd260c61fafed06a00e109a4ca0c6209afcbc2f
First added on: Feb 13, 2025